DENTSPLY SIRONA Inc. (NASDAQ:XRAY)‘s stock had its “neutral” rating restated by equities researchers at UBS AG in a research note issued on Thursday, www.flashratings.com reports. They currently have a $59.00 price objective on the medical instruments supplier’s stock, down from their prior price objective of $62.00. UBS AG’s price objective indicates a potential upside of 6.31% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on XRAY. Zacks Investment Research upgraded DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a report on Wednesday, April 12th. Goldman Sachs Group, Inc. (The) cut DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and cut their price target for the company from $60.00 to $55.00 in a research note on Tuesday, May 23rd. Cleveland Research upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 23rd. BidaskClub cut DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Saturday, June 10th. Finally, HC Wainwright assumed coverage on DENTSPLY SIRONA in a research note on Tuesday, July 11th. They issued a “buy” rating and a $74.00 price target for the company. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. DENTSPLY SIRONA currently has an average rating of “Buy” and an average target price of $66.75.

Shares of DENTSPLY SIRONA (NASDAQ XRAY) traded down 1.30% during mid-day trading on Thursday, reaching $55.50. The company had a trading volume of 3,521,178 shares. The company has a market capitalization of $12.72 billion, a price-to-earnings ratio of 35.71 and a beta of 1.26. The firm’s 50-day moving average is $63.39 and its 200 day moving average is $62.35. DENTSPLY SIRONA has a 12 month low of $55.00 and a 12 month high of $65.68.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.65. The firm had revenue of $992.70 million for the quarter, compared to the consensus estimate of $1 billion. DENTSPLY SIRONA had a return on equity of 7.37% and a net margin of 9.42%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.76 earnings per share. On average, equities research analysts predict that DENTSPLY SIRONA will post $2.78 earnings per share for the current year.

WARNING: “DENTSPLY SIRONA’s (XRAY) “Neutral” Rating Reiterated at UBS AG” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/dentsply-sironas-xray-neutral-rating-reiterated-at-ubs-ag/1469767.html.

A number of hedge funds have recently bought and sold shares of the stock. Alps Advisors Inc. boosted its stake in shares of DENTSPLY SIRONA by 0.3% in the second quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock worth $488,000 after buying an additional 20 shares during the period. Ropes Wealth Advisors LLC boosted its stake in shares of DENTSPLY SIRONA by 0.3% in the first quarter. Ropes Wealth Advisors LLC now owns 9,003 shares of the medical instruments supplier’s stock worth $562,000 after buying an additional 29 shares during the period. Wetherby Asset Management Inc. boosted its stake in shares of DENTSPLY SIRONA by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock worth $324,000 after buying an additional 30 shares during the period. HighTower Advisors LLC boosted its stake in shares of DENTSPLY SIRONA by 0.6% in the first quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 39 shares during the period. Finally, Atria Investments LLC boosted its stake in shares of DENTSPLY SIRONA by 1.5% in the second quarter. Atria Investments LLC now owns 4,541 shares of the medical instruments supplier’s stock worth $294,000 after buying an additional 68 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.